Evidence map›Paper›PMID 39021795›Full record

ArticleiScience2024

The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma.

Yue Zeng, Xing-Xiang Pu, Feng-Jiao He, Chun-Hong Hu, Hong Zhu, Yan Huang, Yu-Rong Peng, Ji-An Zou, Jun-Qi Liu, Sheng-Hao Shi and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yue ZengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Xing-Xiang PuDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.
Feng-Jiao HeDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Chun-Hong HuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Hong ZhuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Yan HuangDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Yu-Rong PengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Ji-An ZouDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Jun-Qi LiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Sheng-Hao ShiDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Yue-Fei LiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Fang MaDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Chao DengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Zhen-Hua QiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Yan-Long LiDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Ying-Zhe ZhangDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Kun HuangDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Xian-Ling LiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Fang WuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The resected pⅢA-N2 non-small-cell lung cancer (NSCLC) patients who could benefit from postoperative radiotherapy (PORT) are not well-defined. The study explored the role of PORT on EGFR mutant and wild-type NSCLC patients. We retrospectively searched for resected pIIIA-N2 lung adenocarcinoma patients who underwent EGFR mutation testing. 80 patients with EGFR wild-type and 85 patients with EGFR mutation were included. 62 patients received PORT. In overall population, the median disease-free survival (DFS) was improved in PORT arm compared to non-PORT arm (22.9 vs. 16.1 months;

Indexed as

CancerDiseaseTherapy

Identifiers

PMID39021795
PMCPMC11253153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.